Literature DB >> 21079637

Blood pressure lowering in patients with diabetes--one level might not fit all.

Rhonda M Cooper-DeHoff1, Eric F Egelund, Carl J Pepine.   

Abstract

Hypertension and diabetes mellitus frequently occur together, leading to increased complications and mortality in patients with both these conditions. Blood pressure (BP) goals for patients with diabetes have consistently been more aggressive than for patients without diabetes. Although the benefits of lowering BP are well documented, data to support this more aggressive goal are lacking. In fact, lowering BP might not always be better. We review the available evidence regarding BP treatment in patients with hypertension and diabetes from randomized clinical trials, as well as available observational data. We also consider evidence related to the J-shaped curve, which reflects the relationship between BP and outcomes in patients with diabetes, and make recommendations for treatment of BP on the basis of a patient's individual risk, as opposed to on the basis of aggressive BP targets recommended by global guidelines. In the future, a personalized approach will maximize the benefits from treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079637      PMCID: PMC3016088          DOI: 10.1038/nrcardio.2010.182

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  64 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

2.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

3.  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

Authors: 
Journal:  Arch Intern Med       Date:  1993-01-25

4.  The epidemiology of impaired glucose tolerance and hypertension.

Authors:  W B Kannel; P W Wilson; T J Zhang
Journal:  Am Heart J       Date:  1991-04       Impact factor: 4.749

5.  Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.

Authors:  George L Bakris; Efrain Gaxiola; Franz H Messerli; Giuseppe Mancia; Serap Erdine; Rhonda Cooper-DeHoff; Carl J Pepine
Journal:  Hypertension       Date:  2004-09-20       Impact factor: 10.190

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

8.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

9.  Treatment-induced blood pressure reduction and the risk of myocardial infarction.

Authors:  M H Alderman; W L Ooi; S Madhavan; H Cohen
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

10.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

View more
  6 in total

1.  Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing?

Authors:  Eve A Kerr; Michelle A Lucatorto; Rob Holleman; Mary M Hogan; Mandi L Klamerus; Timothy P Hofer
Journal:  Arch Intern Med       Date:  2012-06-25

2.  Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.

Authors:  R V Seimon; D Espinoza; L Ivers; V Gebski; N Finer; U F Legler; A M Sharma; W P T James; W Coutinho; I D Caterson
Journal:  Int J Obes (Lond)       Date:  2014-01-10       Impact factor: 5.095

3.  Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: angiotensin-converting enzyme inhibitors.

Authors:  Eberhard Ritz
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04       Impact factor: 3.738

Review 4.  Blood pressure j-curve: current concepts.

Authors:  Maciej Banach; Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

5.  Decision tree-based modelling for identification of potential interactions between type 2 diabetes risk factors: a decade follow-up in a Middle East prospective cohort study.

Authors:  Azra Ramezankhani; Esmaeil Hadavandi; Omid Pournik; Jamal Shahrabi; Fereidoun Azizi; Farzad Hadaegh
Journal:  BMJ Open       Date:  2016-12-01       Impact factor: 2.692

6.  The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice.

Authors:  Patricio Lopez-Jaramillo; Jose Lopez-Lopez; Cristina Lopez-Lopez; Miguel I Rodriguez-Alvarez
Journal:  Diabetol Metab Syndr       Date:  2014-03-04       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.